Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients Receiving Trastuzumab, Pertuzumab, and Docetaxel or Paclitaxel With or Without Carboplatin: HALT-D

Trial Profile

Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients Receiving Trastuzumab, Pertuzumab, and Docetaxel or Paclitaxel With or Without Carboplatin: HALT-D

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Jun 2018

At a glance

  • Drugs Crofelemer (Primary)
  • Indications Diarrhoea
  • Focus Therapeutic Use
  • Acronyms HALT-D
  • Most Recent Events

    • 08 Jun 2018 Planned number of patients changed from 46 to 52.
    • 08 Jun 2018 Planned End Date changed from 1 May 2019 to 1 Dec 2019.
    • 08 Jun 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top